Phase II, randomized, double blinded, placebo control, toxicity/efficacy study on the transfer of adenovirus with the CD40 ligand gene (AdcuCD40L) to patients with stage I, II or III esophageal carcinoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs CD154 gene therapy (Primary)
- Indications Oesophageal cancer
- Focus Pharmacogenomic; Therapeutic Use
- 04 May 2016 Biomarkers information updated
- 04 Aug 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Aug 2011 Planned end date changed from 1 Aug 2012 to 31 Jul 2011 as reported by ClinicalTrials.gov.